Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Share-based Compensation data on record, last reported at $4.8 million in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 53.41% year-over-year to $4.8 million; the TTM value through Sep 2025 reached $49.0 million, down 1.65%, while the annual FY2024 figure was $67.3 million, 22.7% up from the prior year.
  • Share-based Compensation reached $4.8 million in Q3 2025 per ZNTL's latest filing, down from $6.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $31.4 million in Q4 2024 and bottomed at $4.8 million in Q3 2025.
  • Average Share-based Compensation over 4 years is $12.4 million, with a median of $12.7 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: soared 125.96% in 2024, then crashed 53.41% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $9.6 million in 2022, then skyrocketed by 44.4% to $13.9 million in 2023, then skyrocketed by 125.96% to $31.4 million in 2024, then tumbled by 84.61% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $4.8 million in Q3 2025, $6.3 million in Q2 2025, and $6.5 million in Q1 2025.